• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket

    4/12/23 8:27:58 AM ET
    $BACK
    $BNRG
    $CIH
    $CMND
    Medical Specialities
    Health Care
    Building Products
    Industrials
    Get the next $BACK alert in real time by email

    Gainers

    • HeartCore Enterprises, Inc. (NASDAQ:HTCR) jumped 119.6% to $1.96 in pre-market trading. HeartCore forged an agreement with rYojbaba Inc for its tenth Go IPO consulting service win.
    • Altamira Therapeutics Ltd. (NASDAQ:CYTO) gained 81.8% to $2.40 in pre-market trading after dropping 36% on Tuesday.
    • Liquid Media Group Ltd. (NASDAQ:YVR) climbed 54.4% to $0.23 in pre-market trading after dropping 17% on Tuesday. Liquid Media Group recently announced it received an additional deficiency notice from Nasdaq.
    • Panbela Therapeutics, Inc. (NASDAQ:PBLA) gained 48.8% to $0.6444 in pre-market trading after gaining 5% on Tuesday. Panbela regained worldwide rights to develop and commercialize FlynpoviTM in patients with familial adenomatous polyposis.
    • Nutex Health Inc. (NASDAQ:NUTX) gained 26.5% to $1.21 in pre-market trading after the company entered into a $100 million pre-paid advance agreement with Yorkville Advisors.
    • Rosecliff Acquisition Corp I (NASDAQ:RCLF) shares climbed 21% to $12.70 in pre-market trading after gaining 5% on Tuesday.
    • China Index Holdings Limited (NASDAQ:CIH) gained 18.5% to $0.8417 in pre-market trading after gaining more than 7% on Tuesday.
    • Jasper Therapeutics, Inc. (NASDAQ:JSPR) surged 12.4% to $1.63 in pre-market trading. On Tuesday, Jasper Therapeutics, named David Hinds, as the Company’s Senior Vice President, Development Operations.
    • Horizon Acquisition Corporation II (NASDAQ:HZON) climbed 11.9% to $11.25 in pre-market trading. Flexjet agreed to terminate business combination with Horizon Acquisition Corporation II.
    • ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) gained 11.2% to $1.88 in pre-market trading.

    Losers

    • PLx Pharma Inc. (NASDAQ:PLXP) fell 22.2% to $0.0938 in pre-market trading after the company received Nasdaq delisting notice.
    • National CineMedia, Inc. (NASDAQ:NCMI) fell 20.9% to $0.1630 in pre-market trading. National CineMedia shares jumped 55% on Tuesday after a 13G filing showed a 9.1% passive stake in the company from AMC Entertainment.
    • Brenmiller Energy Ltd (NASDAQ:BNRG) shares dropped 17% to $1.95 in pre-market trading after surging 74% on Tuesday.
    • Virgin Orbit Holdings, Inc. (NASDAQ:VORB) fell 15% to $0.1003 in pre-market. Virgin Orbit Holdings shares dropped around 30% on Tuesday after the company received a delisting notice.
    • iMedia Brands, Inc. (NASDAQ:IMBI) fell 13.5% to $0.45 in pre-market trading after reporting weaker-than-expected Q4 results.
    • CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) fell 12.5% to $0.6120 in pre-market trading after dropping over 6% on Tuesday. CNS Pharmaceuticals recently announced it received approval from the Competent Authority and the central Ethics Committee in Italy for its potentially pivotal global trial evaluating Berubicin for the treatment of GBM.
    • IMAC Holdings, Inc. (NASDAQ:BACK) fell 12.5% to $0.1645 in pre-market trading after jumping 50% on Tuesday.
    • Siyata Mobile Inc. (NASDAQ:SYTA) fell 12.3% to $0.1120 in pre-market trading. Siyata Mobile recently received $600,000+ order from U.S. School District.
    • Clearmind Medicine Inc. (NASDAQ:CMND) shares fell 12.1% to $0.4701 in pre-market trading after gaining around 25% on Tuesday. Clearmind Medicine recently announced a $3.5 million public offering priced at $0.78 per share.
    • Professional Diversity Network, Inc. (NASDAQ:IPDN) fell 11.4% to $2.57 in pre-market trading after dropping 56% on Tuesday. Professional Diversity Network recently acquired additional 20% stake in RemoteMore USA.

    Now Read This: S&P 500 Closes Flat, Market Volatility Increases Slightly

    Get the next $BACK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BACK
    $BNRG
    $CIH
    $CMND

    CompanyDatePrice TargetRatingAnalyst
    Jasper Therapeutics Inc.
    $JSPR
    1/13/2026$17.00Buy
    Rodman & Renshaw
    National CineMedia Inc.
    $NCMI
    10/31/2025$7.00 → $6.50Outperform
    Barrington Research
    Jasper Therapeutics Inc.
    $JSPR
    7/8/2025$4.00Outperform → Market Perform
    BMO Capital Markets
    Jasper Therapeutics Inc.
    $JSPR
    7/8/2025$5.00Outperform → Sector Perform
    RBC Capital Mkts
    Jasper Therapeutics Inc.
    $JSPR
    7/7/2025Overweight → Neutral
    Cantor Fitzgerald
    Jasper Therapeutics Inc.
    $JSPR
    7/7/2025Outperform → Mkt Perform
    William Blair
    National CineMedia Inc.
    $NCMI
    5/16/2025$6.00Buy → Neutral
    B. Riley Securities
    National CineMedia Inc.
    $NCMI
    3/14/2025$7.50Neutral → Outperform
    Wedbush
    More analyst ratings

    $BACK
    $BNRG
    $CIH
    $CMND
    SEC Filings

    View All

    SEC Form DEFA14A filed by Nutex Health Inc.

    DEFA14A - Nutex Health Inc. (0001479681) (Filer)

    3/13/26 4:02:10 PM ET
    $NUTX
    Real Estate

    SEC Form DEF 14A filed by Nutex Health Inc.

    DEF 14A - Nutex Health Inc. (0001479681) (Filer)

    3/13/26 4:01:49 PM ET
    $NUTX
    Real Estate

    SEC Form 6-K filed by Clearmind Medicine Inc.

    6-K - Clearmind Medicine Inc. (0001892500) (Filer)

    3/13/26 7:46:36 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BACK
    $BNRG
    $CIH
    $CMND
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Bates Jon Christian bought $102,532 worth of shares (750 units at $136.71), increasing direct ownership by 15% to 5,638 units (SEC Form 4)

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    11/28/25 2:11:24 PM ET
    $NUTX
    Real Estate

    Director Wiggans Thomas G bought $99,630 worth of Voting Common Stock (41,000 units at $2.43) (SEC Form 4)

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    9/24/25 4:01:57 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Lucas Svetlana bought $48,600 worth of Voting Common Stock (20,000 units at $2.43) (SEC Form 4)

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    9/24/25 4:01:38 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BACK
    $BNRG
    $CIH
    $CMND
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Jasper Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $17.00

    1/13/26 10:20:49 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barrington Research reiterated coverage on National Cinemedia with a new price target

    Barrington Research reiterated coverage of National Cinemedia with a rating of Outperform and set a new price target of $6.50 from $7.00 previously

    10/31/25 7:55:49 AM ET
    $NCMI
    Advertising
    Consumer Discretionary

    Jasper Therapeutics downgraded by BMO Capital Markets with a new price target

    BMO Capital Markets downgraded Jasper Therapeutics from Outperform to Market Perform and set a new price target of $4.00

    7/8/25 8:30:26 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BACK
    $BNRG
    $CIH
    $CMND
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

    Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030 Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat

    3/13/26 7:45:00 AM ET
    $CMND
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Brenmiller Energy CEO Avi Brenmiller Issues Letter to Shareholders

    Tel Aviv, Israel--(Newsfile Corp. - March 12, 2026) - Brenmiller Energy Ltd. (NASDAQ:BNRG) ("Brenmiller", "Brenmiller Energy" or the "Company"), a provider of integrated power and heat solutions for industrial and utility customers built around its proprietary thermal energy storage ("TES") technology, today issued a letter from its Chief Executive Officer, Avi Brenmiller. Dear Shareholders,I am writing to you at a pivotal moment for Brenmiller Energy.It has taken us almost fifteen years to reach this point and realize the vision that set us on this journey: replacing fossil fuel-based industrial heat generation with clean, reliable energy. Today, we are beginning to see our vision translate

    3/12/26 8:07:00 AM ET
    $BNRG
    Building Products
    Industrials

    Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

    Vancouver, Canada, March 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the continuation of participant enrollment for the third cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). The recruitment follows the positive topline results recently reported from the secon

    3/11/26 9:07:00 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BACK
    $BNRG
    $CIH
    $CMND
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Nutex Health Inc.

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/11/26 6:27:50 PM ET
    $NUTX
    Real Estate

    SEC Form 4 filed by Nutex Health Inc.

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/11/26 6:08:03 PM ET
    $NUTX
    Real Estate

    SEC Form 4 filed by Nutex Health Inc.

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/11/26 5:52:21 PM ET
    $NUTX
    Real Estate

    $BACK
    $BNRG
    $CIH
    $CMND
    Leadership Updates

    Live Leadership Updates

    View All

    Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

    Vancouver, Canada, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received final approval from the Hadassah Medical Center, Jerusalem, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable Hadassah Medical Center, a leading clinical site in Israel, to join the Company's clinical trial, of which the fir

    11/13/25 8:54:39 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPDN Welcomes His Highness Shaikh Ali Sultan Al Nuaimi of the UAE Royal Family as Independent Director

    CHICAGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Professional Diversity Network, Inc. (NASDAQ:IPDN) ("IPDN" or the "Company"), a technology holding company focused on the application of AI technologies and AI-powered solutions, today announced the appointment of His Highness Shaikh Ali Sultan Al Nuaimi, a distinguished member of the Ajman Royal Family of the United Arab Emirates, to its Board of Directors as an Independent Director, effective as of November 5, 2025. This appointment is intended to support IPDN's planned strategic expansion into the Middle East and reflects its focus on global digital innovation. His Highness Shaikh Ali Sultan Al Nuaimi has an extensive background in both busine

    11/7/25 8:20:00 AM ET
    $IPDN
    Computer Software: Programming Data Processing
    Technology

    Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

    Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced the appointment of Mary-Elizabeth Gifford as Chief of Global Impact. In this role, Gifford will lead efforts to strengthen Clearmind's US partnerships, governmental and regulatory advocacy, and strategic alliances in Washington, D.C. and New York, bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines. Prior to joining Cl

    10/27/25 9:22:00 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BACK
    $BNRG
    $CIH
    $CMND
    Financials

    Live finance-specific insights

    View All

    NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM

    FULL YEAR 2025 HIGHLIGHTS:Total revenue of $875.3 million for the year 2025 versus $479.9 million for the year 2024, an increase of 82.4%Net income attributable to Nutex Health of $70.8 million for 2025 versus net income of $52.1 million for 2024, an increase of $18.7 millionDiluted EPS of $10.48 for 2025 versus diluted EPS of $9.69 for 2024EBITDA of $168.6 million for 2025 versus $98.8 million for 2024, an increase of 70.6%Adjusted EBITDA of $259.6 million for 2025 versus $102.8 million for 2024, an increase of 152.6%Net cash from operating activities of $248.1 million for 2025HOUSTON, March 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), today ann

    3/5/26 6:33:00 PM ET
    $NUTX
    Real Estate

    National CineMedia, Inc. Reports Results for Fiscal Fourth Quarter and Full Year 2025

    Fourth quarter operating income increases year-over-year and fourth quarter adjusted OIBDA exceeds guidance Fourth quarter revenue growth of 8% outpaced attendance as NCM attracted greater advertiser demand National CineMedia, Inc. (NASDAQ:NCMI) (the "Company" or "NCM"), the managing member of National CineMedia, LLC (NCM LLC), the operator of the largest cinema advertising platform in the U.S., announced today its consolidated results for the fiscal fourth quarter and year ended January 1, 2026. "NCM expanded fourth quarter revenue by 8% year-over-year, demonstrating the returns from our continued investment in our platform over the course of the year," said Tom Lesinski, Chief Execu

    2/26/26 4:05:00 PM ET
    $AMC
    $CNK
    $NCMI
    Movies/Entertainment
    Consumer Discretionary
    Advertising

    Nutex Health Schedules 2025 Fourth Quarter and Year-End Financial Results and Earnings Conference Call

    HOUSTON, Feb. 25, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, on Thursday, March 5, 2026, after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, March 6, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and

    2/25/26 5:29:00 PM ET
    $NUTX
    Real Estate

    $BACK
    $BNRG
    $CIH
    $CMND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Brenmiller Energy Ltd

    SC 13D/A - Brenmiller Energy Ltd. (0001901215) (Subject)

    12/5/24 11:18:20 AM ET
    $BNRG
    Building Products
    Industrials

    Amendment: SEC Form SC 13D/A filed by National CineMedia Inc.

    SC 13D/A - National CineMedia, Inc. (0001377630) (Subject)

    11/20/24 9:34:56 PM ET
    $NCMI
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Siyata Mobile Inc.

    SC 13G/A - Siyata Mobile Inc. (0001649009) (Subject)

    11/14/24 7:28:44 PM ET
    $SYTA
    Telecommunications Equipment
    Telecommunications